# CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.

> **NCT03671460** · PHASE1 · UNKNOWN · sponsor: **Tianjin Mycure Medical Technology Co., Ltd** · enrollment: 18 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** CD19 CAR-T cells

## Key facts

- **NCT ID:** NCT03671460
- **Lead sponsor:** Tianjin Mycure Medical Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-07
- **Primary completion:** 2020-01-01
- **Final completion:** 2021-01-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2018-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03671460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03671460, "CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03671460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*